---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-076768"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:46:45.101408+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cytek Q4 revenue $62.1M (+8% YoY); net loss $44.1M on $38.1M deferred tax valuation allowance

## Summary
- Full-year 2025 revenue $201.5M (+1% YoY); Q4 set record quarterly revenue.
- GAAP gross margin 53% in Q4 vs 59% a year ago; adjusted gross margin 55% vs 61%.
- Full-year net loss $66.5M vs $6.0M in 2024, driven by $33.1M non-cash deferred tax valuation allowance and higher expenses.
- Adjusted EBITDA for 2025 was $5.0M, down from $22.4M; excluding investment income, was $(3.1)M.
- Guides FY2026 revenue of $205-212M, representing 2-5% growth over 2025.

## SEC filing metadata
- accession: 0001193125-26-076768
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312526076768/0001193125-26-076768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312526076768/d106442d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-076768
- JSON: https://secwatch.observer/filing/0001193125-26-076768.json
- Plain text: https://secwatch.observer/filing/0001193125-26-076768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.